跳转到主要内容

Innovative design concepts in tumor-targeting peptide-drug conjugates\: Insights into emerging applications

中华医学杂志(英文版) 2026 年第 139 卷第 2 期 222-232 页

DOI:10.1097/CM9.0000000000003438

10

作者人数

5

被引次数

来源:Crossref,截至 2026-10-20

作者

  1. 1
    Ruirong Tan 第一作者
  2. 2
    Zhenya Yang
  3. 3
    Jun Xie

    四川大学华西医院

  4. 4
    Zijun Wu
  5. 5
    Shanshan Guo
  6. 6
    Li Li
  7. 7
    Zhujun Yin
  8. 8
    Hua Hua
  9. 9
    Miao Liu
  10. 10
    Rui Li

参考文献 共 84 条

  1. 1 Antibody-drug conjugates in HER2-positive breast cancer 10.1097/cm9.0000000000001932
  2. 2 A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy 10.3389/fphar.2023.1274088
  3. 3 Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies 10.1007/s13346-024-01564-3
  4. 4 Neoantigens in precision cancer immunotherapy: From identification to clinical applications 10.1097/cm9.0000000000002181
  5. 5 Antibody–drug conjugates come of age in oncology 10.1038/s41573-023-00709-2
  6. 6 Unlocking the potential of antibody–drug conjugates for cancer therapy 10.1038/s41571-021-00470-8
  7. 7 Current status of surgical treatment of rectal cancer in China 10.1097/cm9.0000000000001076
  8. 8 Small molecule–and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment 10.1002/psc.3561
  9. 9 Small molecule-drug conjugates: Opportunities for the development of targeted anticancer drugs 10.1002/cmdc.202300720
  10. 10 Peptide-drug conjugates: A new hope for cancer management 10.3390/molecules27217232
  11. 11 Peptide-drug conjugates: Design, chemistry, and drug delivery system as a novel cancer theranostic 10.1021/acsptsci.3c00269
  12. 12 Tumor-penetrating peptide for systemic targeting of Tenascin-C 10.1038/s41598-020-62760-y
  13. 13 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors 10.1080/17474124.2019.1685381
  14. 14 Lutetium-177 DOTATATE: A practical review 10.1016/j.prro.2022.02.002
  15. 15 NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 10.1016/s1470-2045(18)30193-1
  16. 16 Phase I study of 99mTc-ADAPT6, a scaffold protein–based probe for visualization of HER2 expression in breast cancer 10.2967/jnumed.120.248799
  17. 17 Affibody-derived drug conjugates targeting HER2: Effect of drug load on cytotoxicity and biodistribution 10.3390/pharmaceutics13030430
  18. 18 Morphological transformation enhances tumor retention by regulating the self-assembly of doxorubicin-peptide conjugates 10.7150/thno.45088
  19. 19 Gemcitabine peptide-based conjugates and their application in targeted tumor therapy 10.3390/molecules26020364
  20. 20 Neurodegenerative disease and brain delivery of therapeutics: Bridging the gap using dendrimers
  21. 21 Berberine prevents diabetic retinopathy through inhibiting HIF-1α/VEGF/ NF-κB pathway in db/db mice
  22. 22 Biomimetic dendrimer–peptide conjugates for early multi-target therapy of Alzheimer’s disease by inflammatory microenvironment modulation
  23. 23 The coming of age of cyclic peptide drugs: An update on discovery technologies 10.1080/17460441.2024.2367024
  24. 24 EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma 10.1002/ijc.31405
  25. 25 BT8009; a nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors 10.1158/1535-7163.mct-21-0875
  26. 26 Peptides as multifunctional players in cancer therapy 10.1038/s12276-023-01016-x
  27. 27 New design of helix bundle peptide−polymer conjugates 10.1021/bm800113g
  28. 28 Peptide–drug conjugates with different linkers for cancer therapy 10.1021/acs.jmedchem.0c01530
  29. 29 Peptide–drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? 10.1016/j.apsb.2022.07.020
  30. 30 Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 10.1038/bjp.2008.260
  31. 31 Learn from antibody–drug conjugates: Consideration in the future construction of peptide-drug conjugates for cancer therapy 10.1186/s40164-022-00347-1
  32. 32 Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer 10.1080/10717544.2018.1435746
  33. 33 Modulating paclitaxel bioavailability for targeting prostate cancer 10.1016/j.bmc.2007.04.029
  34. 34 Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice
  35. 35 Organic carbamates in drug design and medicinal chemistry 10.1021/jm501371s
  36. 36 The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity 10.1002/cmdc.201000478
  37. 37 More than toxins—current prospects in designing the next generation of antibody drug conjugates 10.31083/j.fbl2708240
  38. 38 Regulated cell death in cancer: From pathogenesis to treatment 10.1097/cm9.0000000000002239
  39. 39 Proteolysis-Targeting Chimeras (PROTACs) in cancer therapy: Present and future 10.3390/molecules27248828
  40. 40 ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155) 10.1200/jco.2018.36.15_suppl.5503
  41. 41 Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study 10.1200/jco.2023.41.16_suppl.3089
  42. 42 Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs 10.1021/jacs.6b12322
  43. 43 Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative 10.1021/ja904411z
  44. 44 Camptothecin’s journey from discovery to WHO Essential Medicine: Fifty years of promise 10.1016/j.ejmech.2021.113639
  45. 45 Design of controlled drug delivery system based on disulfide cleavage trigger 10.1021/jp507763a
  46. 46 Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel 10.1038/s41551-020-0597-7
  47. 47 Selective neuropeptide Y conjugates with maximized carborane loading as promising boron delivery agents for boron neutron capture therapy 10.1021/acs.jmedchem.9b01136
  48. 48 Progress and future directions with peptide–drug conjugates for targeted cancer therapy 10.3390/molecules26196042
  49. 49 Peptide–drug conjugates: An emerging direction for the next generation of peptide therapeutics 10.1021/acs.jmedchem.3c01835
  50. 50 Peptide drugs: A new direction in cancer immunotherapy
  51. 51 Active targeting gold nanoparticle for chemotherapy drug delivery: A Review
  52. 52 Peptide–drug conjugate-based nanocombination actualizes breast cancer treatment by maytansinoid and photothermia with the assistance of fluorescent and photoacoustic images 10.1021/acs.nanolett.9b00770
  53. 53 Enzymatic hydrogelation of small molecules 10.1021/ar7001914
  54. 54 Supramolecular hydrogelators and hydrogels: From soft matter to molecular biomaterials 10.1021/acs.chemrev.5b00299
  55. 55 A peptide-based material for therapeutic carbon monoxide delivery 10.1039/c2sm25785h
  56. 56 Self-assembly behaviours of peptide–drug conjugates: Influence of multiple factors on aggregate morphology and potential self-assembly mechanism 10.1098/rsos.172040
  57. 57 Supramolecular crafting of self-assembling camptothecin prodrugs with enhanced efficacy against primary cancer cells 10.7150/thno.15420
  58. 58 Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery 10.1016/j.actbio.2020.05.026
  59. 59 Type I collagen is thermally unstable at body temperature 10.1073/pnas.032307099
  60. 60 Enzyme-triggered self-assembly of peptide hydrogels via reversed hydrolysis 10.1021/ja056549l
  61. 61 Capilliposide from Lysimachia capillipes promotes terminal differentiations and reverses paclitaxel resistance in A2780T cells of human ovarian cancer by regulating Fos/Jun pathway
  62. 62 Supramolecular Self-assembly of a Model Hydrogelator: Characterization of Fiber Formation and Morphology 10.3390/gels2040027
  63. 63 Dephosphorylation of D-peptide derivatives to form biofunctional, supramolecular nanofibers/hydrogels and their potential applications for intracellular imaging and intratumoral chemotherapy 10.1021/ja404215g
  64. 64 Synthesis and biological characterization of monomeric and tetrameric RGD-cryptophycin conjugates 10.1002/chem.201905437
  65. 65 The ligand binding mechanism to purine nucleoside phosphorylase elucidated via molecular dynamics and machine learning 10.1038/ncomms7155
  66. 66 A designed cyclic peptide based on trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability 10.1016/j.bioorg.2021.105453
  67. 67 Multivalency increases the binding strength of RGD peptidomimetic-paclitaxel conjugates to integrin αVβ3 10.1002/chem.201703093
  68. 68 Effects of a novel cyclic RGD peptidomimetic on cell proliferation, migration and angiogenic activity in human endothelial cells 10.1186/2045-824x-6-11
  69. 69 In vivo tumor growth inhibition and antiangiogenic effect of cyclic NGR peptide-daunorubicin conjugates developed for targeted drug delivery 10.1007/s12253-019-00773-3
  70. 70 Peptide drug conjugates and their role in cancer therapy 10.3390/ijms24010829
  71. 71 Aldehyde PEGylation of laccase from trametes versicolor in route to increase its stability: Effect on enzymatic activity 10.1002/jmr.2405
  72. 72 Anti-inflammatory effects of PEGylated human adrenomedullin in a mouse DSS-induced colitis model 10.1002/ddr.21383
  73. 73 Tumor vasculature-targeting PEGylated peptide–drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis 10.1016/j.ejmech.2021.113430
  74. 74 Synthesis and preclinical evaluation of a novel, selective 111In-labelled aminoproline-RGD-peptide for non-invasive melanoma tumor imaging 10.1039/c5md00301f
  75. 75 New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration 10.1021/jm9016637
  76. 76 Targeting the hypoxic and acidic tumor microenvironment with pH-sensitive peptides 10.3390/cells10030541
  77. 77 Peptides as a platform for targeted therapeutics for cancer: Peptide–drug conjugates (PDCs) 10.1039/d0cs00556h
  78. 78 A brand new era of cancer immunotherapy: Breakthroughs and challenges 10.1097/cm9.0000000000001490
  79. 79 New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: Mechanisms and therapeutic opportunities 10.1186/s40164-022-00356-0
  80. 80 Research advances in peptide–drug conjugates 10.1016/j.apsb.2023.02.013
  81. 81 The role of the symbiotic microecosystem in cancer: Gut microbiota, metabolome, and host immunome 10.3389/fimmu.2023.1235827
  82. 82 Molecular mechanisms of anti-cancer bioactivities of seaweed polysaccharides
  83. 83 Renovation of old drugs’–can peptide drug conjugates lead the post-ADC era? 10.1071/ch22252
  84. 84 Abnormal O-GlcNAcylation of Pax3 occurring from hyperglycemia-induced neural tube defects is ameliorated by carnosine but not folic acid in chicken embryos 10.1007/s12035-015-9581-8

数据来源

论文信息:
中华医学期刊网、Crossref
作者名单:
Crossref
被引次数:
Crossref,截至 2026-10-20
参考文献:
Crossref

论文的著作权归作者与出版方所有,本站只整理公开的题录信息并附原文链接,不构成任何医疗建议。